Brii Biosciences Executes New Buyback: 131,500 Shares Acquired for HKD0.12 Million

Bulletin Express10-27 20:20

Brii Biosciences Limited disclosed that on 27 October 2026 it repurchased 131,500 ordinary shares on the Hong Kong Stock Exchange, paying a volume-weighted average price of HKD0.94 per share within a price range of HKD0.92–0.95. The total consideration was approximately HKD0.12 million.

Following the transaction, Brii Biosciences’ outstanding share count decreased from 721.60 million to 721.47 million shares, while treasury shares rose from 13.85 million to 13.98 million. The overall issued share capital remained unchanged at 735.45 million shares, as the repurchased stock is being held in treasury rather than cancelled.

The buyback was executed under the repurchase mandate granted on 16 June 2026, which authorises the company to repurchase up to 72.19 million shares. Including the latest transaction, Brii Biosciences has repurchased 1.26 million shares year-to-date, equivalent to 0.17% of its issued share base on the mandate date.

In accordance with Hong Kong listing regulations, the company is subject to a moratorium on issuing new shares or disposing of treasury shares until 26 November 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment